Investors aim to spotlight ties between pricing, exec pay by Eric Sagonowsky Tuesday, April 23, 2019 With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.
Loyalty pays: Merck CEO Ken Frazier scores 19% raise by Arlene Weintraub Wednesday, April 10, 2019 Ken Frazier’s total compensation for 2018 was $20.9 million, up from $17.6 million in 2017, enough to put him among the industry's highest paid.
Merck CEO follows father's advice to 'tune out' critics by Arlene Weintraub Tuesday, March 26, 2019 Merck CEO Kenneth Frazier remains unflustered by his company's challenges, thanks to advice his father gave him when he was a teenager in Philadelphia.
5. Merck & Co. by Carly Helfand It’s not hard to see how Merck grew its revenues in 2018, what with Keytruda’s sales swelling by billions. But the PD-1 superstar wasn’t in it alone.
Pharma CEOs in Washington: The latest from the Senate pricing hearing by Eric Sagonowsky Tuesday, February 26, 2019 Once the Senate finance committee’s drug pricing hearing started on Tuesday, it didn’t take long for sparks to fly.
Big Pharma CEOs decide to show up at Senate pricing hearings by Eric Sagonowsky Wednesday, February 6, 2019 Sen. Charles Grassley, R-Iowa, vowed to haul pharma CEOs into Senate drug-pricing hearings. Now, several have heeded the call.
Merck analysts to CEO Frazier: What’s so great about the pipeline? by Arlene Weintraub Friday, February 1, 2019 Merck's 2019 sales expectations are on the low side of what analysts expected, intensifying concerns about growth beyond I-O star Keytruda.
Merck's long M&A dry spell isn't for lack of trying: CEO by Carly Helfand Tuesday, January 8, 2019 There’s a reason Merck hasn’t made a big acquisition lately. And it’s not because it doesn’t want to.
Merck, Pfizer CEOs strike discordant tones on drug prices by Eric Sagonowsky Friday, November 2, 2018 There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.
Merck CEO scouts growth beyond high-flying Keytruda by Arlene Weintraub Thursday, October 25, 2018 Merck & Co. has a jet engine for growth in its oncology star Keytruda, but long-term it needs more than cancer to keep growth coming.
